XNAS · Diagnostics & Research
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$179.38-2.03%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Technical
- Quality & growth
What to watch
- Valuation
Quality & growth
30%58Positive
- Revenue growth 42.7%
- EPS growth n/a
Valuation
25%14Weak
- P/E -52.6
- EV/Sales 20.5
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
#409 by market cap in our coverage · ~2,506 employees · Listed 2018-10-04 · www.guardanthealth.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (industry)Top 11%
Gross margin (industry)Top 18%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
80/100Strong
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 2 sell · 2 neutral of 8 votes
TickerWhale reads GH's technical setup as strong at 80/100, not yet ranked against the universe in this run. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+49.1%
- vs 50-day+11.4%
Momentum
Mixed
- RSI (14)63 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength14· weak trend
- MACD (12,26,9)buy(histogram 1.739)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 2 sell · 2 neutral.
Result — 4 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-52.6 · TTM loss
- P/S (TTM)20.1
- P/B—
- EV/EBITDA—
- EV/Sales20.5
- PEG—
Profitability & returns
- Gross margin65.0%
- Net margin-38.3%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)42.7%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $23.8B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GHCurrentGuardant Health | — | 80 | -52.6 | — | — | 20.5 | $179.38 | -2.03% | +42.7% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.